GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report) crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $20.68 and traded as low as $20.03. GENMAB A/S/S shares last traded at $20.92, with a volume of 1,872,721 shares trading hands.
GENMAB A/S/S Stock Up 6.2 %
The company’s 50 day moving average price is $20.68 and its 200 day moving average price is $23.22.
About GENMAB A/S/S
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Further Reading
- Five stocks we like better than GENMAB A/S/S
- Health Care Stocks Explained: Why You Might Want to Invest
- NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
- Financial Services Stocks Investing
- Up 50% in January, Twilio’s Pullback Is the Time to Buy
- What Do S&P 500 Stocks Tell Investors About the Market?
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
